Anti-mitotic potential of 7-diethylamino-3(2′-benzoxazolyl)-coumarin in 5-fluorouracil-resistant human gastric cancer cell line SNU620/5-FU

被引：31
|
作者：
Kim, Nam Hyun [2 ]
Kim, Su-Nam [3 ]
Oh, Joa Sub [4 ]
Lee, Seokjoon [5 ]
Kim, Yong Kee [1 ]
机构：
[1] Sookmyung Womens Univ, Pharmacol Lab, Coll Pharm, Seoul 140742, South Korea
[2] Kwandong Univ Coll Med, Dept Pharmacol, Kangnung 210701, South Korea
[3] KIST Gangneung Inst, Kangnung 210340, South Korea
[4] Dankook Univ, Coll Pharm, Cheonan 330714, South Korea
[5] Kwandong Univ Coll Med, Dept Basic Sci, Kangnung 210701, South Korea
来源：
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2012年 / 418卷 / 04期
基金：
新加坡国家研究基金会;
关键词：
7-Diethylamino-3(2 '-benzoxazolyl)-coumarin; Microtubule; Drug resistance; 5FU; AURORA KINASES; DRUGS; AGENTS; MICROTUBULES; INHIBITORS; THERAPY; TARGET;
D O I：
10.1016/j.bbrc.2012.01.049
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
In this study, we investigate an anti-mitotic potential of the novel synthetic coumarin-based compound, 7-diethylamino-3(2'-benzoxazolyl)-coumarin, in 5-fluorouracil-resistant human gastric cancer cell line SNU-620-5FU and its parental cell SNU-620. It exerts the anti-proliferative effects with similar potencies against both cancer cells, which is mediated by destabilization of microtubules and subsequent mitotic arrest. Furthermore, this compound enhances caspase-dependent apoptotic cell death via decreased expression of anti-apoptotic genes. Taken together, our data strongly support anti-mitotic potential of 7-diethylamino-3(2'-benzoxazolyl)-coumarin against drug-resistant cancer cells which will prompt us to further develop as a novel microtubule inhibitor for drug-resistant cancer chemotherapy. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码：616 / 621
页数：6
相关论文
共 11 条
  • [1] Efficacy of nab-paclitaxel on 5-fluorouracil (5-FU) resistant human gastric cancer cell lines
    Nukatsuka, Mamoru
    Kobunai, Takashi
    Matsuoka, Kazuaki
    Takechi, Teiji
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [2] Cryptotanshinone Inhibits the Proliferation of 5-Fluorouracil-Resistant Gastric Cancer SGC-7901/5-FU Cells Via the JAK2/STAT3 Pathway
    Cao, Yezhi
    Wang, Linghu
    Cheng, Ling
    Chu, Jun
    Yu, Qingsheng
    Peng, Hui
    Wu, Wenkai
    Liu, Haiwei
    Zhou, Fuhai
    Shu, Yaqian
    Zhang, Qi
    [J]. PHARMACEUTICAL CHEMISTRY JOURNAL, 2024, 58 (02) : 187 - 196
  • [3] A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics
    Zhang, Chi
    Ma, Qunfeng
    Shi, Yinan
    Li, Xue
    Wang, Ming
    Wang, Junfeng
    Ge, Jianlin
    Chen, Zhinan
    Wang, Ziling
    Jiang, Hong
    [J]. ONCOLOGY REPORTS, 2017, 37 (05) : 2942 - 2954
  • [4] Isolation of 5-FU and CDDP-resistant mutants from a human gastric scirrhous cancer cell line, HSC-39
    Murase, Hiroko
    Okunaka, Mashiro
    Koike, Atsushi
    Tamaki, Rie
    Yanagihara, Kazuyoshi
    Amano, Fumio
    [J]. CANCER SCIENCE, 2018, 109 : 967 - 967
  • [5] Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines
    Kawabata, Rumi
    Oie, Shinji
    Takahashi, Masayuki
    Kanayama, Hiroomi
    Oka, Toshinori
    Itoh, Kohji
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (06) : 1489 - 1500
  • [6] Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2
    Jordan, A
    Stein, J
    [J]. EUROPEAN JOURNAL OF NUTRITION, 2003, 42 (06) : 324 - 331
  • [7] Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2
    Angela Jordan
    Jürgen Stein
    [J]. European Journal of Nutrition, 2003, 42 : 324 - 331
  • [8] Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-κB and Bcl-2 signaling pathways
    Xu, Gui-yun
    Tang, Xiao-jun
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2017, 92 : 95 - 107
  • [9] Multicenter phase 2 trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG15021
    Ueda, A.
    Muranaka, T.
    Kawamoto, Y.
    Sawada, K.
    Nakatsumi, H.
    Harada, K.
    Kobayashi, Y.
    Miyagishima, T.
    Hatanaka, K.
    Dazai, M.
    Kawahata, S.
    Sasaki, T.
    Sasaki, Y.
    Kato, S.
    Shinada, K.
    Tsuji, Y.
    Yuki, S.
    Sakamoto, N.
    Nishimoto, N.
    Sakata, Y.
    Komatsu, Y.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 48 - 48
  • [10] The Anticancer Effect of (1S,2S,3E,7E,11E)-3,7,11,15-Cembratetraen-17,2-olide(LS-1) through the Activation of TGF-β Signaling in SNU-C5/5-FU, Fluorouracil-Resistant Human Colon Cancer Cells
    Kim, Eun-Ji
    Kang, Jung-Il
    Kwak, Jeon-Won
    Jeon, Chan-Hee
    Nguyen-Huu Tung
    Kim, Young-Ho
    Choi, Cheol-Hee
    Hyun, Jin-Won
    Koh, Young-Sang
    Yoo, Eun-Sook
    Kang, Hee-Kyoung
    [J]. MARINE DRUGS, 2015, 13 (03): : 1340 - 1359
12